Karachi: GlaxoSmithKline Pakistan Limited announced its financial results for the quarter ending March 31, 2026, revealing a notable increase in profit after taxation compared to the previous year. The Board of Directors, during their meeting on April 27, 2026, reported a profit after taxation of Rs. 2,610,704,000, a significant move of 22.76% from Rs. 2,126,547,000 recorded in the same period last year.

According to information available from the Pakistan Stock Exchange (PSX), the company’s revenue from contracts with customers increased to Rs. 17,028,325,000 from Rs. 15,580,140,000, marking a very large move in revenue. The gross profit for the quarter stood at Rs. 6,383,362,000, up from Rs. 5,325,889,000, indicating a big move in profitability.

The company’s operating profit also saw a significant increase, rising to Rs. 4,311,353,000 from Rs. 3,634,150,000 in the previous year. This increase can be attributed to a combination of higher revenue and controlled expenses. Selling, marketing, and distribution expenses rose to Rs. 1,295,896,000 from Rs. 1,064,216,000, while administrative expenses increased to Rs. 582,550,000 from Rs. 538,152,000. Other operating expenses also saw an increase to Rs. 375,472,000 from Rs. 308,636,000.

The company did not declare any cash dividend, bonus shares, right shares, or any other corporate actions for this period. Furthermore, no other price-sensitive information was reported.

GlaxoSmithKline Pakistan’s total assets increased to Rs. 53,990,416,000 from Rs. 50,683,502,000 at the end of December 2025. The equity of the company also witnessed growth, reaching Rs. 36,285,337,000 from Rs. 33,674,633,000.

The company’s financial stability is further evidenced by its improved earnings per share, which rose from Rs. 6.68 to Rs. 8.20, reflecting enhanced shareholder value. The reserves increased to Rs. 33,100,665,000 from Rs. 30,489,961,000, while the liabilities stood at Rs. 17,705,079,000, slightly up from Rs. 17,008,869,000.

Overall, GlaxoSmithKline Pakistan Limited showcased a robust performance in the first quarter of 2026, with substantial gains in revenue, profit, and asset growth, underscoring its strong position in the designated market category.